CGRP/SP–Piezo2 Signaling in Trigeminal Neuralgia

Trigeminal neuralgia (TN) is defined by severe, brief orofacial pain triggered by otherwise innocuous mechanical stimuli. Although compression of the trigeminal root entry zone is a frequent clinical association, the cellular events that convert compression into persistent mechanical allodynia remain incompletely resolved. In the open-access study by Liao and colleagues, published in Cellular & Molecular Biology Letters, chronic trigeminal root entry zone compression is used to connect neuroinflammation with mechanosensory amplification through a CGRP/SP–Piezo2 axis. The reference paper is available through the published study.

Study Background and Research Question

The study addresses a central problem in TN biology: how can a local lesion or compression event produce hypersensitivity to light touch in the facial skin? Previous work has implicated trigeminal ganglion inflammation, neuropeptide release, and altered mechanosensation, but these processes have often been investigated separately. Piezo2 is particularly relevant because it is a mechanically activated ion channel involved in touch perception and can contribute to calcium influx after activation.

Liao et al. asked whether chronic compression of the trigeminal root entry zone produces a coordinated response across the trigeminal ganglion (TG) and the whisker pad, and whether this response is organized around Piezo2, calcitonin gene-related peptide (CGRP), substance P (SP), and intracellular Ca2+ signaling. A second question was causal: does manipulating cAMP-related signaling, PKC activity, or Piezo2 expression alter the mechanical allodynia phenotype?

Key Innovation from the Reference Study

The principal innovation is the proposed integration of three biological layers that are often treated independently: neuroinflammation, neuropeptide signaling, and mechanotransduction. The authors describe a Ca2+-CGRP/SP-Piezo2 positive-feedback loop in which inflammatory or purinergic stimulation increases neuropeptide and Piezo2 expression, while Piezo2-mediated depolarization and Ca2+ entry can further support neuronal sensitization.

A second important finding is the identification of a TG neuron–Merkel cell axis in the whisker pad. Piezo2, the CGRP receptor complex formed by CRLR and RAMP1, and the SP receptor NK1R were reported to be co-expressed in rat Merkel cells. This anatomical relationship provides a plausible peripheral site at which sensory nerve-derived peptides and mechanically sensitive epithelial cells could interact. It also shifts the interpretation of TN beyond a purely neuronal disorder by incorporating specialized skin-associated mechanosensory cells.

The study further places PKC and cAMP-related signaling upstream of this sensitized state. PKC was associated with increased Piezo2, CGRP, and SP expression in the TG and whisker pad, whereas local inhibition of cAMP signaling reduced mechanical allodynia. Importantly, these observations do not establish that every cAMP effect is mediated exclusively by PKA; rather, they identify cAMP-sensitive signaling as a manipulable component of the peripheral pain circuit.

Methods and Experimental Design Insights

The experimental design combines an in vivo TN model with tissue-level localization, behavioral analysis, molecular perturbation, and in vitro mechanistic experiments. Chronic compression of the trigeminal root entry zone was used to induce a TN-like state in rats. Orofacial mechanical sensitivity was then assessed in the whisker pad, allowing the investigators to relate molecular changes in peripheral tissues to a clinically relevant trigger modality.

At the tissue level, the authors examined expression and localization of Piezo2, CGRP, SP, CRLR/RAMP1, and NK1R in the TG and whisker pad. The co-expression analysis in Merkel cells was especially valuable because it supports a cellular framework for peptide–mechanotransduction coupling rather than relying only on bulk tissue measurements.

Causality was tested through several complementary interventions. Local manipulation of cAMP signaling in the whisker pad was used to determine whether this pathway contributes to allodynia. Conversely, dibutyryl-cAMP was used to enhance cAMP signaling, and Piezo2 knockdown in the TG and whisker pad was used to test whether Piezo2 is required for the resulting hypersensitivity. PKC-related regulation was also investigated in both peripheral compartments.

For the cellular mechanism, extracellular ATP served as an inflammatory or danger-associated stimulus. The in vitro experiments examined whether ATP increases CGRP and SP expression and whether it also induces Piezo2. The reported involvement of Ca2+-dependent ERK1/2 and p38 MAPK cascades, together with transcription-factor-dependent regulation, provides a signaling bridge between extracellular purinergic stimulation and changes in mechanosensory gene expression.

Protocol Parameters

• Animal model: Use chronic trigeminal root entry zone compression when modeling the compression-associated TN phenotype described in the reference study; experimental timing and surgical details should be taken directly from the original methods.
• Behavioral endpoint: Quantify whisker-pad mechanical sensitivity before and after pathway manipulation so that molecular changes can be aligned with the allodynia phenotype.
• Peripheral pathway testing: Compare local cAMP-pathway inhibition with dibutyryl-cAMP enhancement, while including untreated and model controls to distinguish pathway reversal from nonspecific behavioral effects.
• Genetic validation: Pair Piezo2 knockdown with expression analysis of CGRP, SP, and relevant receptors in both TG and whisker-pad samples.
• Cellular mechanism: In ATP-stimulated cultures, evaluate Ca2+ dependence and ERK1/2 or p38 MAPK involvement using orthogonal molecular and pharmacological controls rather than inferring pathway order from expression changes alone.

Core Findings and Why They Matter

First, chronic root compression was associated with a neuroinflammatory response involving the TG and whisker pad. The findings support the view that peripheral tissue changes are not merely downstream markers of pain but may actively maintain abnormal mechanical sensitivity.

Second, the study links PKC activity to increased expression of Piezo2, CGRP, and SP. This is significant because it provides a potential explanation for how inflammatory signaling can alter both the chemical environment and the mechanical responsiveness of the sensory apparatus. The result also suggests that changes in Piezo2 abundance may be regulated rather than being a passive consequence of nerve injury.

Third, local inhibition of cAMP signaling alleviated mechanical allodynia, while Piezo2 knockdown significantly reduced the allodynia produced by dibutyryl-cAMP. This bidirectional design strengthens the proposed relationship between cAMP-sensitive signaling and Piezo2-dependent mechanosensitivity. It also indicates that Piezo2 may function downstream of, or in parallel with, cAMP-driven sensitization.

Fourth, extracellular ATP increased CGRP and SP expression and induced Piezo2 through Ca2+-dependent ERK1/2 and p38 MAPK signaling. These data offer a molecular explanation for positive feedback: ATP and inflammatory signals elevate neuropeptide output and mechanosensory capacity, while Piezo2 activation can increase Ca2+ entry and reinforce intracellular signaling. The model therefore connects neuroinflammation to the physical stimulus that triggers TN pain.

For researchers, the broader implication is methodological as well as biological. A study of mechanical allodynia should not rely solely on behavioral measurements or neuronal markers. Integrating sensory-cell localization, neuropeptide receptor status, Ca2+ signaling, and loss-of-function experiments can reveal the tissue-level circuit responsible for persistent hypersensitivity.

Comparison with Existing Internal Articles

The available internal resources approach the cAMP/PKA signaling pathway primarily from an assay-development perspective. A guide focused on cAMP/PKA signaling assays is most relevant for interpreting phosphorylation-based readouts and neuronal response experiments. A second resource on optimizing cAMP pathway workflows complements the reference study by emphasizing reproducibility, controls, and quantitative assay design.

These resources should be viewed as complementary rather than as evidence for the TN mechanism itself. Liao et al. use cAMP manipulation as part of an in vivo mechanistic framework that includes TG–Merkel cell signaling and Piezo2 knockdown. The internal articles are more useful when translating that conceptual framework into controlled phosphorylation, imaging, or cell-based experiments.

Limitations and Transferability

The study provides a coherent mechanistic model, but several limitations affect its transferability. First, the evidence comes from a rat compression model. This model captures important features of compression-associated TN, yet human TN is clinically heterogeneous and may include vascular compression, demyelination, structural remodeling, and patient-specific inflammatory states.

Second, co-expression of Piezo2, CGRP receptors, and NK1R in Merkel cells supports a proposed signaling site but does not by itself prove direct functional communication between every cell population. The knockdown experiments strengthen the causal interpretation of Piezo2, although incomplete knockdown, tissue heterogeneity, and compensatory mechanosensory pathways remain possible.

Third, cAMP manipulation and PKC-associated changes do not fully resolve pathway hierarchy. cAMP can influence multiple effectors, and expression-based measurements cannot determine whether altered Piezo2 reflects transcriptional regulation, trafficking, membrane stability, or a combination of these processes. Similarly, ATP is a broad extracellular signal, so its effects may depend on receptor composition, cell type, exposure conditions, and inflammatory context.

Finally, the positive-feedback model is strongest as a framework for peripheral sensitization. It should not be interpreted as evidence that the same pathway explains central pain processing, long-term clinical progression, or therapeutic response in patients. Human tissue studies, cell-type-specific perturbations, and longitudinal analyses will be needed to test those extensions.

Research Support Resources

For experiments that isolate the PKA component of cAMP-dependent protein kinase inhibition, researchers can use H 89 2HCl (SKU B2190), also described as N-(2-(p-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide. Product information reports a PKA Ki of 48 nM and substantially weaker activity against several other kinases, while also documenting a broader inhibition profile at higher concentrations. It has been used to study protein phosphorylation modulation and forskolin-induced neurite outgrowth inhibition without lowering intracellular cAMP. Because of these additional kinase activities, concentration-response controls and genetic validation are important when applying this potent PKA inhibitor to TN-related cAMP experiments; reported cell-assay use is commonly around 30–50 μM, but the appropriate concentration should be established for the specific model.